CytomX Therapeutics, Inc. (CTMX) Insider Trading
Over the last 3 months, CTMX insiders made 0 open-market buys and 4 sales, a net sale of -$1.2M (SEC Form 4). Over the last 6 months, 104 institutions increased and 53 reduced their position (13F).
Insider Activity
Sentiment
0/100
Buys (3m)
0
Sells (3m)
4
Net (3m)
-$1.2M
Insider trades by month Buys Sells
Mar
Aug
Mar
Jun
Nov
Mar
Context3-month price -33.3%Institutions accumulating (13F)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Mar 19, 2026 | BELVIN MARCIAofficer: SVP, Chief Scientific Officer | Sell | 31,492 | $6.42 |
| Mar 19, 2026 | McCarthy Sean A.director, officer: CEO | Sell | 118,969 | $6.42 |
| Mar 19, 2026 | Ogden Christopherofficer: Chief Financial Officer | Sell | 19,323 | $6.42 |
| Mar 19, 2026 | Chu Yu-Wayeofficer: Chief Medical Officer | Sell | 21,279 | $6.42 |
| Feb 4, 2026 | Chu Yu-Wayeofficer: Chief Medical Officer | Grant | 75,000 | — |
| Feb 4, 2026 | McCarthy Sean A.director, officer: CEO | Grant | 210,000 | — |
| Feb 4, 2026 | BELVIN MARCIAofficer: SVP, Chief Scientific Officer | Grant | 60,000 | — |
| Feb 4, 2026 | Chu Yu-Wayeofficer: Chief Medical Officer | Grant | 300,000 | $6.09 |
| Feb 4, 2026 | McCarthy Sean A.director, officer: CEO | Grant | 980,000 | $6.09 |
| Feb 4, 2026 | Ogden Christopherofficer: Chief Financial Officer | Grant | 90,000 | — |
| Feb 4, 2026 | Lester Rachaelofficer: Chief Business Officer | Grant | 50,000 | $6.09 |
| Feb 4, 2026 | Lester Rachaelofficer: Chief Business Officer | Grant | 20,000 | — |
| Feb 4, 2026 | Ogden Christopherofficer: Chief Financial Officer | Grant | 325,000 | $6.09 |
| Feb 4, 2026 | BELVIN MARCIAofficer: SVP, Chief Scientific Officer | Grant | 250,000 | $6.09 |
| Nov 10, 2025 | McCarthy Sean A.director, officer: CEO | Sell | 101,793 | $4.54 |
| Oct 29, 2025 | Lester Rachaelofficer: Chief Business Officer | Grant | 650,000 | $3.74 |
| Sep 30, 2025 | Chu Yu-Wayeofficer: Chief Medical Officer | Grant | 87,500 | $2.90 |
| Sep 30, 2025 | BELVIN MARCIAofficer: SVP, Chief Scientific Officer | Grant | 36,300 | $2.90 |
| Sep 30, 2025 | Ogden Christopherofficer: Chief Financial Officer | Grant | 78,250 | $2.90 |
| Sep 30, 2025 | McCarthy Sean A.director, officer: CEO | Grant | 570,000 | $2.90 |
| Sep 30, 2025 | McCarthy Sean A.director, officer: CEO | Grant | 285,000 | — |
| Sep 30, 2025 | Ogden Christopherofficer: Chief Financial Officer | Grant | 39,150 | — |
| Sep 30, 2025 | Chu Yu-Wayeofficer: Chief Medical Officer | Grant | 43,750 | — |
| Sep 30, 2025 | BELVIN MARCIAofficer: SVP, Chief Scientific Officer | Grant | 18,150 | — |
| Jun 17, 2025 | Ogden Christopherofficer: Chief Financial Officer | Option | 37,500 | — |
| Jun 17, 2025 | McCarthy Sean A.director, officer: CEO | Option | 150,000 | — |
| Jun 17, 2025 | BELVIN MARCIAofficer: SVP, Chief Scientific Officer | Option | 37,500 | — |
| Jun 17, 2025 | BELVIN MARCIAofficer: SVP, Chief Scientific Officer | Sell | 13,884 | $2.69 |
| Jun 17, 2025 | McCarthy Sean A.director, officer: CEO | Sell | 55,511 | $2.69 |
| Jun 17, 2025 | Ogden Christopherofficer: Chief Financial Officer | Sell | 1,641 | $2.95 |
Source: CTMX SEC Form 4 filings, latest Mar 19, 2026. For informational purposes only — not investment advice.
Institutional activity (13F)
How institutions changed their CTMX positions over the last 6 months (SEC Form 13F).
Increased
104
New positions
116
Reduced
53
Sold out
40
Largest moves
| Institution | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 32.0M | May 15, 2026 |
| FMR LLC | Increased | 24.7M | Feb 17, 2026 |
| PERCEPTIVE ADVISORS LLC | Increased | 20.2M | May 29, 2026 |
| VR ADVISER, LLC | Unchanged | 15.6M | Feb 17, 2026 |
| KYNAM CAPITAL MANAGEMENT, LP | Increased | 15.0M | May 15, 2026 |
| BANK OF AMERICA CORP /DE/ | Increased | 10.2M | May 18, 2026 |
| VR ADVISER, LLC | Reduced | 10.0M | May 15, 2026 |
| PERCEPTIVE ADVISORS LLC | Unchanged | 9.7M | Feb 17, 2026 |
| KYNAM CAPITAL MANAGEMENT, LP | Increased | 9.0M | Feb 17, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 8.7M | May 15, 2026 |
| VANGUARD GROUP INC | Reduced | 8.5M | Jan 29, 2026 |
| POINT72 ASSET MANAGEMENT, L.P. | Increased | 7.9M | May 15, 2026 |
| COMMODORE CAPITAL LP | Unchanged | 7.7M | Feb 17, 2026 |
| STATE STREET CORP | Increased | 5.7M | May 15, 2026 |
| CITADEL ADVISORS LLC | Increased | 5.4M | May 15, 2026 |
Source: SEC Form 13F filings. For informational purposes only — not investment advice.